Lanzhou University Second Hospital

Running trials

• Not yet recruiting

  Treatment Strategy for Patients With RA-ILD

  NCT07643038· Phase 4· Chinese SLE Treatment And Research Group· Source

• Recruiting

  A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

  NCT07867080· Phase 3· 4D Molecular Therapeutics· Source

• Recruiting

  Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre

  NCT07687186· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source

• Recruiting

  Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study

  NCT07673640· ShanShan Li· Source

• Not yet recruiting

  Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

  NCT07569757· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT

  NCT07589413· Zhiping Wang· Source

• Recruiting

  Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer

  NCT07424560· Zhilong Dong· Source

• Not yet recruiting

  Topefilgrastim Injection in the Treatment of High-Risk Pregnant Patients With Preeclampsia

  NCT07384936· Fang Wang· Source

• Active, not recruiting

  Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

  NCT07162883· Phase 3· Qilu Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Pfizer· Source

• Active, not recruiting

  A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

  NCT07160335· Phase 1· Shanghai Henlius Biotech· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Effects of Enhanced External Counterpulsation Combined With Cardiac Rehabilitation in Patients With Atrial Fibrillation

  NCT07058987· Lanzhou University Second Hospital· Source

• Not yet recruiting

  A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests

  NCT07087041· Beijing Friendship Hospital· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

  NCT07483450· Phase 4· Hoffmann-La Roche· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

  NCT06991257· Phase 2· Pfizer· Source

• Recruiting

  Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer

  NCT07029269· Phase 3· Zuoyi Jiao· Source

• Not yet recruiting

  Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer

  NCT07007286· Peking University First Hospital· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

  NCT06949033· Phase 3· Zuoyi Jiao· Source

• Recruiting

  Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

  NCT06862869· Hoffmann-La Roche· Source

• Recruiting

  Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

  NCT06925243· Phase 3· Zuoyi Jiao· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Daiichi Sankyo· Source

• Recruiting

  To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension

  NCT07051811· Lepu Medical Technology (Beijing) Co., Ltd.· Source

• Not yet recruiting

  The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).

  NCT06606509· Nanjing First Hospital, Nanjing Medical University· Source

• Active, not recruiting

  A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

  NCT06551324· Phase 3· Pfizer· Source

• Recruiting

  Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema

  NCT07515079· Phase 3· Bio-Thera Solutions· Source

• Active, not recruiting

  A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

  NCT06559163· Phase 2· Zenas BioPharma (USA), LLC· Source

• Active, not recruiting

  A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)

  NCT06238843· Phase 3· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

  NCT06300177· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

  NCT06155084· Phase 1/2· Hinova Pharmaceuticals Inc.· Source

• Active, not recruiting

  A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.

  NCT05987358· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Active, not recruiting

  Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis

  NCT06174402· Phase 2/3· Han Ying· Source

• Recruiting

  A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

  NCT05837897· Phase 3· Takeda· Source

• Recruiting

  Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

  NCT05862337· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Active, not recruiting

  A Study of Telitacicept for IgA Nephropathy (TELIGAN)

  NCT05799287· Phase 3· RemeGen Co., Ltd.· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  FlashPoint Renal Denervation Under Columbus 3D Mapping System Guidance for Treating Hypertension

  NCT05590871· Shanghai Hongdian Medical CO., LTD· Source

• Recruiting

  Post-market European & Asian Registry to Evaluate the Minos™ Stent-Graft and Delivery System in Abdominal Aortic Aneurysm Treatment

  NCT07674173· Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd· Source

• Recruiting

  Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis

  NCT05751967· Phase 3· Xijing Hospital of Digestive Diseases· Source

• Active, not recruiting

  Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT05479994· Phase 2· BeiGene· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05528510· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  China HeadAche DIsorders RegiStry

  NCT05334927· Beijing Tiantan Hospital· Source

Showing 50 of 63.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure5 recruiting
• Gastric and oesophageal cancer4 recruiting
• High blood pressure4 recruiting
• Crohn's disease3 recruiting
• Bladder cancer2 recruiting
• Coronary artery disease2 recruiting
• Diabetic eye disease2 recruiting
• Hepatitis B2 recruiting
• Liver and biliary tract cancer2 recruiting
• Lung cancer2 recruiting
• Aortic aneurysm1 recruiting
• Atrial fibrillation1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Liver cirrhosis1 recruiting
• Migraine1 recruiting
• Multiple myeloma1 recruiting
• Pancreatic cancer1 recruiting
• Primary biliary cholangitis1 recruiting
• Prostate cancer1 recruiting
• Rheumatoid arthritis1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

  NCT06738979· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients

  NCT06778538· Shang Panfeng· Source

• Completed

  Evaluation of ENPP1 Expression and Immune Response in Bladder Cancer Patients

  NCT06657755· Lanzhou University Second Hospital· Source

• Completed

  A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema

  NCT06422507· Phase 3· Bayer· Source

• Completed

  Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

  NCT06241313· Phase 3· AbbVie· Source

• Completed

  A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.

  NCT06089278· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Completed

  Head Position After Endovascular Therapy

  NCT06115707· Zhengzhou Yuan· Source

• Completed

  A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

  NCT06010303· Phase 2· BeiGene· Source

• Terminated

  Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

  NCT06206278· Phase 2· LianBio LLC· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

  NCT05975268· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

  NCT07030595· Phase 3· Alebund Pharmaceuticals· Source

• Completed

  Gallstones and Risk of Inflammatory Bowel Disease

  NCT05882006· Hepatopancreatobiliary Surgery Institute of Gansu Province· Source

• Completed

  A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

  NCT05810038· Phase 3· Pfizer· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Study of Telitacicept in Generalized Myasthenia Gravis

  NCT05737160· Phase 3· RemeGen Co., Ltd.· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

  NCT05529992· Phase 3· Takeda· Source

• Completed

  Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

  NCT05522231· Phase 2/3· Hutchmed· Source

• Completed

  Correlation Between Prostate-specific Membrane Antigen Positron Emission Tomography and Arterial Spin Labeling Perfusion Imaging in Glioblastoma

  NCT06600399· Lanzhou University Second Hospital· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Amgen· Source

• Completed

  A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

  NCT05083923· Phase 3· Biogen· Source

• Completed

  A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

  NCT05093933· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

  NCT05003245· Phase 3· Shanghai Henlius Biotech· Source

• Completed

  Phase III Study on HMPL-523 for Treatment of ITP

  NCT05029635· Phase 3· Hutchmed· Source

• Completed

  A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

  NCT05047263· Phase 3· Bayer· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

  NCT04740671· Phase 3· Shanghai Henlius Biotech· Source

• Completed

  Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

  NCT05359068· Phase 3· Shanghai Pharmaceuticals Holding Co., Ltd· Source

• Terminated

  To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Phase 3· Incyte Corporation· Source

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Phase 3· Incyte Corporation· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

  NCT04847557· Phase 3· Eli Lilly and Company· Source

• Completed

  Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

  NCT04732494· Phase 2· BeiGene· Source

• Completed

  Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

  NCT04805307· Phase 1· Keymed Biosciences Co.Ltd· Source

• Completed

  A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

  NCT04574284· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

  NCT04435626· Phase 3· Bayer· Source

• Completed

  Study on AI Recognition System Of Heart Sound In Congenital Heart Disease Screening

  NCT04307030· Xinhua Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source

• Completed

  TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

  NCT03952091· Phase 3· TJ Biopharma Co., Ltd.· Source

• Completed

  Effect of Blood Pressure on Cardiovascular Outcomes and Recurrence After Catheter Ablation in Patients With Atrial Fibrillation

  NCT06433336· Lanzhou University Second Hospital· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Gastric and oesophageal cancer73 works · 11 trials
• Bladder cancer57 works · 3 trials
• Osteoporosis28 works · 0 trials
• Kidney cancer21 works · 3 trials
• Neuromyelitis optica (NMOSD)8 works · 0 trials
• Trigeminal neuralgia3 works · 0 trials